March 08, 2021
Article
Consideration of how immunotherapy may influence other allergic diseases, patient adherence options, and advancing assessment of peanut allergy options.
March 06, 2021
Younger patients are faring better, and for longer, with sublingual immunotherapy. A leading investigator discusses what more needs to be learned in the burgeoning field.
March 02, 2021
A pooled analysis of sleep disturbance-related outcomes showed the IgE inhibitor significantly benefits a burdensome symptom of CRSwNP.
Video
From interpreting currently-understood risks to managing isolation-induced indoor allergen exposure, asthmatics may have concerns they address with clinicians.
A review of 3 new studies, which indicate the association between severe COVID-19 and the chronic disease is more intricate than previously thought.
February 28, 2021
From better education, to remote monitoring and consistent check-ins, clinicians may need to initiate better adherence in their younger, severely ill patients.
How dupilumab is observed to benefit EoE patients—and who may administer the biologic therapy.
An interview on the TSLP inhibitor's effect on exacerbations, hospitalizations, and disease progress over 52-week findings.
In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.
Perspective on how the interleukin-targeting biologic has unique benefit for the rare, under-resourced disease.
